Mechanical Circulatory Support for Acute Myocardial Infarction Cardiogenic Shock: Review and Recent Updates.

Area of Science:

• Cardiology
• Critical Care Medicine
• Biomedical Engineering

Background:

• Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) is a critical condition leading to systemic hypoperfusion, multiorgan failure, and high mortality.
• Mechanical circulatory support (MCS) devices are employed to manage AMI-CS, with various technologies offering different hemodynamic benefits.
• Despite available MCS options, mortality rates in AMI-CS remain a significant clinical challenge.

Purpose of the Study:

• To review the current landscape of MCS devices used in cardiogenic shock complicating acute myocardial infarction.
• To compare the efficacy and limitations of different MCS strategies, including intra-aortic balloon pumps, percutaneous ventricular assist devices, extracorporeal membrane oxygenation, and microaxial flow pumps.
• To highlight the evolving role of microaxial flow pumps in improving outcomes for AMI-CS patients.

Main Methods:

• Review of existing literature on mechanical circulatory support devices in cardiogenic shock.
• Analysis of pathophysiological characteristics and clinical outcomes associated with different MCS devices.
• Comparison of mortality data and complication rates across various MCS technologies in the context of AMI-CS.

Main Results:

• Intra-aortic balloon pumps and percutaneous ventricular assist devices have not demonstrated mortality reduction in the revascularization era.
• Venoarterial extracorporeal membrane oxygenation provides complete cardiopulmonary support but lacks proven mortality benefit in major trials.
• Microaxial flow pumps, such as Impella devices, have shown a significant decrease in mortality in the AMI-CS population, albeit with a higher incidence of device-related complications.

Conclusions:

• Management of AMI-CS requires individualized clinical assessment due to the lack of a universally effective MCS device.
• While microaxial flow pumps demonstrate a mortality benefit, careful consideration of their associated complication rates is essential.
• Ongoing research and technological advancements are crucial for refining MCS strategies, enhancing device safety, and improving patient survival in cardiogenic shock.